<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195529</url>
  </required_header>
  <id_info>
    <org_study_id>OSTEOGEN</org_study_id>
    <nct_id>NCT04195529</nct_id>
  </id_info>
  <brief_title>Genetic Polymorphisms Associated With Vertebral Osteochondrosis</brief_title>
  <acronym>OSTEOGEN</acronym>
  <official_title>Evaluation of Polymorphisms in the Vitamin D Receptor and Involved in Inflammation Associated With Vertebral Osteochondrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Galeazzi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Galeazzi</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is proposed for the identification of phenotype, biochemical and genetic
      markers in adult symptomatic spinal osteochondrosis to promote the early diagnosis of this
      pathological condition and to establish possible therapeutic targets that favor a
      conservative approach aimed at treating patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary outcome is to determine the association between specific phenotypic
      characteristics of osteochondrosis, in particular linked to osteo-cartilaginous degeneration,
      with the identified vitamin D receptor genotypes.

      The secondary outcomes are to evaluate the circulating levels of the osteo-cartilage
      degradation markers, of the vitamin D and to evaluate the association of the osteochondrosis
      phenotype with variants in genes involved in inflammatory processes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>association of spinal osteochondrosis with specific VDR genotypes</measure>
    <time_frame>1st year</time_frame>
    <description>Determine the association between specific phenotypic characteristics of osteochondrosis identified by means of MRI, in particular the presence of wavy/Irregular, notched endplates or Shmorl's nodes with FokI, BsmI, ApaI, TaqI VDR genotypes, assessed by means of TaqMan SNP Genotyping Assays</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>association of spinal osteochondrosis with specific biochemical markers</measure>
    <time_frame>2nd year</time_frame>
    <description>Determine the association between specific phenotypic characteristics of osteochondrosis identified by means of MRI, in particular the presence of wavy/Irregular, notched endplates or Shmorl's nodes with the circulating levels of the osteo-cartilage degradation markers CTx-I, CTx-II and of the vitamin D.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>association of spinal osteochondrosis with specific inflammatory genotypes</measure>
    <time_frame>1st year</time_frame>
    <description>Exploratory evaluation of the association of the osteochondrosis phenotype with variants in genes involved in inflammatory processes, such as IL-1B and IL-1RN.</description>
  </other_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Spinal Osteochondrosis</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>presence of genetic variants</intervention_name>
    <description>identification of the presence of genetic variants</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        70-100 adult male and female patients suffering from osteochondrosis and disc degeneration
        evidenced by MRI will be enrolled, after signing the informed consent, at the Galeazzi
        Orthopedic Institute.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria

          -  males and females

          -  18≤age ≤ 65 years old

          -  patients with adult spinal osteochondrosis Exclusion criteria

          -  age &lt; 18 or &gt; 65 years old

          -  chronic major diseases such as diabetes, autoimmune diseases, cardiovascular diseases,
             malignancies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandra Colombini</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Istituto Ortopedico Galeazzi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alessandra Colombini</last_name>
    <phone>0266214067</phone>
    <email>alessandra.colombini@grupposandonato.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elena Cittera</last_name>
    <phone>0266214057</phone>
    <email>elena.cittera@grupposandonato.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS Istituto ortopedico Galeazzi</name>
      <address>
        <city>Milano</city>
        <state>Milan</state>
        <zip>20161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Colombini</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteochondrosis</mesh_term>
    <mesh_term>Spinal Osteochondrosis</mesh_term>
    <mesh_term>Scheuermann Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

